Coffee and Heart Health: What 30 Years of Research Actually Says

A stethoscope and a stainless-steel mug on a table

Photo: Frederick Shaw / Unsplash, Unsplash License.

This article reports published research. It is not medical advice, and nothing in it is a recommendation to start, stop, increase or reduce coffee consumption. If you have an arrhythmia, high blood pressure, heart failure or any cardiac diagnosis, or you take medication that interacts with caffeine, ask your own physician before changing what you drink.

The sections below set out what published research has found about coffee and the heart, name the study behind every figure, and state where the evidence is thin or where researchers disagree.

What Kind of Evidence This Is

Almost all of it is observational: large groups are asked what they drink, then followed for years. That design shows association. It does not show cause.

The American Heart Association's 2026 scientific statement on caffeine lists this among the factors that complicate the evidence: most studies are observational and prone to unmeasured and residual confounding, with a small but growing number of randomised trials. Its conclusions call for more randomised trials, such as crossover or pragmatic trials, wherever feasible.

Coffee drinking travels with other habits, smoking above all: the 2014 meta-analysis by Ding and colleagues judged that the higher risk seen with heavy coffee drinking in age-adjusted analyses was likely due to confounding by smoking. The same authors note that existing disease, especially hypertension, could lead to reverse causation, with people changing what they drink after a diagnosis. A second difficulty is specific to coffee: the AHA statement notes that much of the evidence concerns coffee rather than caffeine itself, so a study reporting a benefit usually cannot say which constituent produced it.

Hold both of those in mind for everything below.

How Caffeine Acts on the Heart

The AHA statement describes how caffeine works. It is absorbed rapidly and metabolised mainly in the liver by the enzyme CYP1A2. It blocks adenosine receptors and raises sympathetic activity, and the statement lists transient increases in blood pressure, blood sugar and alertness among its short-term effects.

That acute effect and the long-term association often point in opposite directions, so they are treated separately below.

Watch: How does caffeine keep us awake? - Hanan Qasim — TED-Ed

The Research That Changed the Story

Large cohort studies then changed the picture. In the Nurses' Health Study and the Health Professionals Follow-up Study, Lopez-Garcia and colleagues reported in 2006 that their data did not provide any evidence that coffee increases the risk of coronary heart disease. A 2015 analysis of those cohorts and the Nurses' Health Study II, by Ding and colleagues, found coffee drinking inversely associated with deaths from cardiovascular disease, among other causes. In the European Prospective Investigation into Cancer and Nutrition, which followed 521,330 people for an average of 16.4 years, Gunter and colleagues reported in 2017 an inverse association between coffee drinking and deaths from circulatory disease among women, hazard ratio 0.78 (0.68–0.90).

The 2014 meta-analysis by Ding and colleagues in Circulation formalised the new picture. It combined 36 prospective cohort studies covering 1,279,804 participants and 36,352 cardiovascular cases, and found the lowest risk at about 3.5 cups a day, a relative risk of 0.85.

The J-Shaped Curve

The relationship is not a straight line. In the Ding meta-analysis, the relative risk of cardiovascular disease was 0.89 at about 1.5 cups a day, lowest at 0.85 at about 3.5 cups, and 0.95, no longer significant, at about 5 cups. The lowest point varies by study and outcome: about 3.5 cups a day for all-cause mortality and 2.5 cups for cardiovascular deaths in the 2019 Kim meta-analysis, and about four cups for heart failure in the AHA statement.

The AHA statement reports the same shape for blood pressure: most studies suggest an inverse J-shaped relationship between naturally occurring caffeinated products and blood pressure.

Where risk turns upward is not settled. The AHA's news release says that more than four cups of caffeinated coffee a day may increase the risk of heart failure, and the statement itself reports that more than four cups a day was associated with worse left ventricular function in the CARDIA cohort. The 2021 heart failure analysis described below could not test high intakes, because too few participants drank more than three cups a day.

Coronary Disease, Stroke and Heart Failure

A painted anatomical teaching model of the human heart on a stand

A heart model, with the position of a persistent ductus arteriosus drawn between the aorta and the pulmonary artery. Photo: Ekko / Wikimedia Commons, public domain.

The AHA statement's summary is that moderate caffeinated coffee consumption is associated with lower risk of coronary artery disease and of stroke, and that low to moderate consumption is associated with lower heart failure risk.

Heart failure. Stevens, Linstead, Hall and Kao applied machine-learning feature selection to the Framingham Heart Study, then tested the result in the ARIC study and the Cardiovascular Health Study. Coffee was the only dietary factor that survived. Per cup per day, the hazard ratio for incident heart failure was 0.95 in Framingham (95% CI 0.91–0.99), 0.86 in the Cardiovascular Health Study (0.78–0.96) and 0.98 in ARIC (0.96–0.99). By dose, compared with no coffee, one cup made no difference, two cups gave 0.69 (0.55–0.87) and three or more gave 0.71 (0.58–0.89).

The Cardiovascular Health Study and ARIC figures are unadjusted; after adjustment for Framingham risk scores they were 0.88 (0.79–0.97) and 0.98 (0.96–1.00), the second only a trend.

The analysis was published in peer-reviewed form in Circulation: Heart Failure in 2021.

The authors' own conclusion is restrained and belongs with the numbers: coffee may be a marker for some other behaviour, and an intentional or prescribed increase in coffee intake to reduce heart failure risk cannot be recommended on the strength of their analysis.

Stroke. A 2024 umbrella review by Gill and colleagues pooled 11 meta-analyses covering 11.96 million individuals and found that up to four cups a day was associated with a 12 per cent lower stroke risk (risk ratio 0.88, 95% CI 0.84–0.92).

That same review also reported a risk ratio of 1.19 for cardiovascular disease in coffee drinkers compared with non-drinkers, and concluded that heavy coffee drinkers had a greater risk of coronary heart disease. The confidence interval for that figure was 0.99 to 1.38, so it did not reach statistical significance, and heterogeneity between the pooled studies was very high, at I² = 84 per cent. When one study was left out to reduce heterogeneity, the pooled risk ratio for coronary heart disease was 1.06 (0.99–1.12), and for very heavy drinkers it was 1.05 (0.98–1.12). The authors list their own limits: they searched one database, and did not distinguish coffee types, cup sizes, brewing methods or additions such as milk and sugar. The review appeared in the Journal of Family Medicine and Primary Care.

Heart Rhythm: Two Randomised Trials

For decades patients with palpitations or atrial fibrillation were told to give up coffee. Two randomised trials have now tested that advice, and they point in different directions for different kinds of irregular beat.

Atrial fibrillation — the DECAF trial. Wong, Marcus and colleagues randomised 200 adults with persistent atrial fibrillation after successful cardioversion. One group was asked to drink at least one cup of caffeinated coffee daily, the other to abstain from coffee and caffeine entirely, for six months. Atrial fibrillation or flutter recurred in 47 per cent of the coffee group and 64 per cent of the abstinence group. For atrial fibrillation alone the hazard ratio was 0.62 (95% CI 0.43–0.91). Participants averaged 69 years of age, and 29.5 per cent were women.

Two limits belong with that result. The trial was open-label, so nobody was blinded, and about a third of the abstinence group later reported drinking at least one cup during the study, which would narrow the gap between the groups rather than widen it. Enrolment ran from November 2021 to December 2024 across five hospitals in the United States, Canada and Australia; the randomised follow-up itself was six months.

Ectopic beats — the CRAVE trial. Marcus and colleagues fitted 100 adults, average age 39, with continuous ECG monitors, accelerometers and glucose monitors, then texted daily instructions over fourteen days to drink caffeinated coffee or avoid caffeine. Premature atrial contractions, the primary outcome, did not differ significantly: 58 a day on coffee days against 53 on caffeine-free days, rate ratio 1.09 (95% CI 0.98–1.20, P = 0.10). Premature ventricular contractions did differ: 154 against 102, rate ratio 1.51 (1.18–1.94). Coffee days also produced about 36 fewer minutes of sleep and about 1,058 more recorded steps.

The AHA statement summarises both: caffeinated coffee reduces recurrent atrial fibrillation but may increase the frequency of premature ventricular contractions. It also notes that high-dose caffeine in purified form has been associated with malignant ventricular arrhythmias, and that findings from ordinary coffee should not be transferred to energy drinks, where case reports have generally suggested harm, mostly arrhythmias.

Decaffeinated Coffee: What the Studies Actually Found

Two studies with different outcomes are reported here. They are separate findings and are kept separate here.

Arrhythmia — Chieng and colleagues, 2022. This UK Biobank analysis followed 449,563 people, median age 58, for an average of 12.5 years, separating ground, instant and decaffeinated coffee. Ground and instant coffee were associated with reduced incident arrhythmia at one to five cups a day; the lowest risk was 4 to 5 cups of ground coffee, hazard ratio 0.83 (95% CI 0.76–0.91), and 2 to 3 cups of instant, 0.88 (0.85–0.92). Decaffeinated coffee was not associated with reduced arrhythmia.

That null result belongs to arrhythmia and to nothing else. In the same study decaffeinated coffee was associated with reduced incident cardiovascular disease — a composite of coronary heart disease, cardiac failure and ischaemic stroke — and with reduced all-cause mortality, the greatest reduction in mortality being at 2 to 3 cups a day, hazard ratio 0.86 (0.81–0.91).

Heart failure — Stevens and colleagues, 2021. A separate finding, from the analysis described above, points the other way. Higher decaffeinated coffee intake was associated with higher heart failure risk in Framingham — hazard ratio 1.10 per cup per day (95% CI 1.03–1.17, P = 0.004) — but showed no association in the Cardiovascular Health Study (P = 0.63). The authors gave three reasons for caution: it appeared in only one cohort; reported decaffeinated intake was low, limiting the analysis; and people with existing cardiovascular risk factors may switch from caffeinated to decaffeinated coffee, which would make decaf look harmful when the risk came first.

Blood Pressure

Caffeine raises blood pressure in the short term. In a 2011 meta-analysis of people with hypertension, Mesas and colleagues found that 200 to 300 mg of caffeine raised systolic pressure by a mean of 8.1 mm Hg and diastolic pressure by 5.7 mm Hg, beginning within the first hour and lasting at least three hours. In three studies that ran for two weeks, coffee did not raise blood pressure compared with a caffeine-free diet or with decaffeinated coffee. The AHA statement says the long-term effects of habitual caffeine on blood pressure remain unclear and are likely minimal, although risk may increase with high intake, particularly in people with severe hypertension. It reports that cohort studies show an inverse J-shaped association with the risk of developing hypertension: a higher risk at 1 to 3 cups a day, and a trend towards lower risk at higher intakes. A Japanese cohort study by Teramoto and colleagues, following 18,609 adults for a median of 18.9 years, found that people with grade 2 to 3 hypertension who drank two or more cups a day had about twice the risk of cardiovascular death of non-drinkers, hazard ratio 2.05 (1.17–3.59).

The European Food Safety Authority, assessing caffeine in 2015, concluded that single doses up to 200 mg — about 3 mg per kilogram of body weight for a 70 kg adult — are unlikely to produce clinically relevant changes in blood pressure in healthy adults.

The AHA statement notes that regular use can lead to tolerance. None of these findings tells an individual with high blood pressure what to do; that is a question for the clinician who manages it.

Cholesterol and the Brewing Method

A paper filter cone and kettle set up for pour-over brewing in a domestic kitchen

Photo: Cerebral726 / Wikimedia Commons, CC BY-SA 4.0.

Here the answer depends on how the coffee was made.

Coffee oils carry two diterpenes, cafestol and kahweol, which raise LDL cholesterol. A paper filter traps them. A metal mesh, or no filter at all, does not. The AHA 2026 statement puts it plainly: no clear relationship is evident between caffeine and blood lipids, but unfiltered coffee raises LDL cholesterol.

Orrje and colleagues measured the difference in 2025 by liquid chromatography–mass spectrometry:

Boiled coffee: 939 mg/L cafestol, 678 mg/L kahweol.
The same boiled coffee poured through a fabric filter: 28 mg/L and 21 mg/L.
Home-brewed paper-filtered coffee: 12 mg/L and 8 mg/L.
Percolator and French press: roughly 90 mg/L cafestol, 70 mg/L kahweol.
Workplace brewing machines: median 176 mg/L cafestol, range 24 to 444.
Some espresso samples: up to 2,447 mg/L cafestol.

Boiled coffee carried about 78 times as much cafestol as the median home-brewed paper-filtered cup. The authors estimated that replacing three cups of machine coffee with paper-filtered coffee, five days a week, would lower LDL cholesterol by 0.58 mmol/L.

The traditional Puerto Rican colador is a cloth filter, described in The Coffee Sock (Colador de Café): Puerto Rico's Original Pour-Over. In the Orrje study a fabric filter cut cafestol in boiled coffee from 939 mg/L to 28 mg/L, a reduction of about 97 per cent. That measurement was made on Swedish boiled coffee through a two-layer polyester and acrylic sock, not on a colador brew, and no published measurement of a colador brew has been located. The mechanism is the same; the number for the colador has not been measured. Stovetop moka pots were not among the brews measured. The AHA statement says cafestol is present to a lesser extent in espresso-based and moka coffee.

Genetic Variation: CYP1A2

CYP1A2 accounts for approximately 95 per cent of caffeine metabolism, a figure reported both in Nehlig's 2018 review in Pharmacological Reviews and in Cornelis and colleagues' 2006 paper in JAMA. An A-to-C substitution at position 734 defines the CYP1A21F allele, which reduces enzyme inducibility. Carriers are slow caffeine metabolisers; people homozygous for CYP1A21A are rapid metabolisers.

How long caffeine stays in the body varies widely. The AHA statement gives its half-life as 2 to 12 hours, and 4 to 5 hours in healthy adults; EFSA gives about four hours, with a range of about two to eight. Smoking speeds its clearance and pregnancy slows it: EFSA reports that by the end of pregnancy the half-life is three to four times longer than before.

Cornelis and colleagues tested whether this changes cardiac risk, in a case-control study of 2,014 people with a first non-fatal myocardial infarction and 2,014 matched controls in Costa Rica between 1994 and 2004, all self-described Hispanic Americans. Fifty-four per cent of controls carried the slow allele. Compared with less than one cup a day, after adjustment:

Intake	Slow metabolisers (*1F carriers)	Rapid metabolisers (1A/1A)
1 cup a day	0.99 (0.69–1.44)	0.75 (0.51–1.12)
2 to 3 cups a day	1.36 (1.01–1.83)	0.78 (0.56–1.09)
4 or more cups a day	1.64 (1.14–2.34)	0.99 (0.66–1.48)

Odds ratios with 95 per cent confidence intervals. Gene–coffee interaction P = 0.04. Cups were 250 ml.

Below the median age of 59 the divergence widened: 2.33 (1.39–3.89) at four or more cups for slow metabolisers against 0.83 (0.46–1.51) for rapid metabolisers, interaction P = 0.003. Below age 50 the slow-metaboliser odds ratio reached 4.07 (1.89–8.74).

This is one case-control study of survivors of non-fatal infarction, and its authors note they cannot exclude an effect on survival after an acute event. The AHA statement says there is insufficient evidence that genetic differences in caffeine metabolism modify the effects of habitual coffee drinking on chronic disease or mortality. It is not a basis for genetic testing, and the AHA statement makes no such recommendation; what the AHA does say is that individual responses vary widely because of genetic differences in metabolism as well as habitual intake, age and other conditions.

All-Cause Mortality

The 2019 meta-analysis by Kim, Je and Giovannucci in the European Journal of Epidemiology, drawing on 40 studies covering 3,852,651 participants, found the lowest all-cause mortality at 3.5 cups a day, a relative risk of 0.85.

The 2022 UK Biobank analysis found the lowest all-cause mortality at 2 to 3 cups a day for every coffee subtype: ground 0.73 (0.69–0.78), instant 0.89 (0.86–0.93) and decaffeinated 0.86 (0.81–0.91).

How Much, According to Whom

Body	Figure	Applies to
American Heart Association statement, 2026	Up to 400 mg caffeine a day, about 3 to 5 cups of 8 oz	Most adults
US Food and Drug Administration, 2024	400 mg a day, about two to three 12 oz cups	Most adults
European Food Safety Authority, 2015	Up to 400 mg a day, habitual	Non-pregnant adults
European Food Safety Authority, 2015	Up to 200 mg in a single dose	Adults
European Food Safety Authority, 2015	Up to 200 mg a day	Pregnant and lactating women
American College of Obstetricians and Gynecologists, 2010, reaffirmed 2026	Less than 200 mg a day	Pregnancy

EFSA also concluded that the information available was insufficient to derive a safe caffeine intake for children and adolescents, and proposed that the adult level of no concern, 3 mg per kilogram of body weight a day, may serve as a basis for them.

The AHA's news release adds that, because of the lack of sufficient, rigorous data, caffeine was not referenced in the Association's 2026 Dietary Guidance to Improve Cardiovascular Health. It also notes that scientific statements inform guidelines but do not make treatment recommendations, so a statement that an intake is safe is not a recommendation to consume it.

Key Facts

Most of the evidence is observational; randomised trials have tested heart rhythm, blood pressure and cholesterol, but not heart attacks, strokes or deaths.
Lowest observed cardiovascular and mortality risk falls in the 2 to 4 cup range across the major meta-analyses, with the exact figure varying by study and outcome.
Unfiltered coffee raises LDL cholesterol; paper-filtered coffee carries very little cafestol.
In the UK Biobank, decaffeinated coffee was linked to lower cardiovascular disease and mortality but not to lower arrhythmia; other studies differ.
Caffeinated coffee reduced recurrent atrial fibrillation in a randomised trial and increased premature ventricular contractions in another.
400 mg of caffeine a day is the reference figure for healthy adults from both the AHA and EFSA; 200 mg a day in pregnancy.
Neither body recommends taking up coffee for cardiovascular reasons.

Frequently Asked Questions

Does coffee cause heart disease? The published evidence does not support that. Moderate caffeinated coffee consumption is associated with lower risk of coronary artery disease, stroke and heart failure in the AHA's 2026 review. Association is not causation, and no randomised trial has tested those endpoints.

Should I give up coffee if I have atrial fibrillation? That is a question for your cardiologist. What can be reported is that the DECAF trial found fewer recurrences among patients who drank about a cup a day after cardioversion than among those who abstained, and that its authors concluded that coffee and other caffeinated products may be reasonably considered in patients with atrial fibrillation. Some people still find caffeine triggers their symptoms. The 2023 American atrial fibrillation guideline states that recommending caffeine abstention to prevent episodes is of no benefit, although it may reduce symptoms in patients who report caffeine as a trigger.

Does decaf give the same heart benefits? Not exactly. Decaffeinated coffee was associated with lower cardiovascular disease and lower mortality in the UK Biobank analysis, but not with the reduced arrhythmia seen for ground and instant coffee. One cohort has linked it to higher heart failure risk in a finding its own authors did not treat as established.

Does coffee raise cholesterol? It depends on the filter, not the caffeine. Paper-filtered coffee carries very little cafestol. Boiled, pressed and some espresso preparations carry a great deal.

Does adding sugar and cream matter? The AHA statement notes that additions such as sugar and cream can counteract potential health benefits, and the Gill umbrella review lists not checking for milk or sugar among its limits. No study located settles how much they change the associations.

How much is too much? The AHA statement treats up to 400 mg of caffeine a day, about 3 to 5 cups of 8 ounces, as safe for most adults; the FDA cites 400 mg, about two to three 12-ounce cups; EFSA also uses 400 mg for non-pregnant adults. EFSA sets 200 mg a day in pregnancy, and ACOG less than 200 mg. None of these figures is a target.

Sources

Marcus GM, Hu FB, van Dam RM, Cornelis MC, Dewland TA, Kang J, Larsson SC, Page RL II, Parekh N. "Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association." Circulation 2026;154(9):e345–e355, published online 20 July 2026. doi:10.1161/CIR.0000000000001454 — the evidence problem; the mechanism; coronary, stroke and heart failure associations; left ventricular function above four cups a day; rhythm findings; purified caffeine and energy drinks; blood pressure, tolerance and long-term effects; lipids and unfiltered coffee; half-life; genetics; additions to the cup; and 400 mg, about 3 to 5 cups.
Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. "Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies." Circulation 2014;129(6):643–659 — 36 cohort studies, 1,279,804 participants, 36,352 cardiovascular cases, lowest risk at about 3.5 cups a day, relative risk 0.85.
Stevens LM, Linstead E, Hall JL, Kao DP. "Association Between Coffee Intake and Incident Heart Failure Risk: A Machine Learning Analysis of the FHS, the ARIC Study, and the CHS." Circulation: Heart Failure 2021;14(2):e006799 — every heart failure hazard ratio by cohort and by dose; the decaffeinated coffee result and the authors' three caveats; and their statement that increased coffee intake cannot be recommended on their results.
Chieng D, Canovas R, Segan L, Sugumar H, Voskoboinik A, Prabhu S, Ling L-H, Lee G, Morton JB, Kaye DM, Kalman JM, Kistler PM. "The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK Biobank." European Journal of Preventive Cardiology 2022;29(17):2240–2249 — 449,563 participants over an average of 12.5 years; ground and instant but not decaffeinated coffee associated with reduced arrhythmia; the cardiovascular and all-cause mortality hazard ratios by subtype.
Wong CX, Cheung CC, Montenegro G, et al., Marcus GM. "Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial." JAMA 2026;335(4):317–325, published online 9 November 2025 — 200 participants; 47 per cent against 64 per cent recurrence; hazard ratio 0.62 for atrial fibrillation alone; the enrolment window, the six-month follow-up, the open-label design and abstinence-group non-adherence.
Marcus GM, Rosenthal DG, Nah G, et al. "Acute Effects of Coffee Consumption on Health among Ambulatory Adults." New England Journal of Medicine 2023;388:1092–1100 — 100 participants; the premature atrial and ventricular contraction rate ratios; the sleep and step-count differences.
Gill H, Patel N, Naik N, Vala L, Rana RK, et al. "An umbrella review of meta-analysis to understand the effect of coffee consumption and the relationship between stroke, cardiovascular heart disease, and dementia among its global users." Journal of Family Medicine and Primary Care 2024;13(11):4783–4796 — 11 meta-analyses, 11.96 million individuals; stroke risk ratio 0.88 (0.84–0.92); cardiovascular disease risk ratio 1.19 (0.99–1.38), I² 84 per cent; and the conclusion on heavy consumption and coronary heart disease; the leave-one-out results; and the authors' stated limits.
Kim Y, Je Y, Giovannucci E. "Coffee consumption and all-cause and cause-specific mortality: a meta-analysis by potential modifiers." European Journal of Epidemiology 2019;34(8):731–752 — 40 studies, 3,852,651 participants, lowest all-cause mortality at 3.5 cups a day, relative risk 0.85.
Nehlig A. "Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption." Pharmacological Reviews 2018;70(2):384–411 — CYP1A2 metabolising approximately 95 per cent of ingested caffeine.
Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. "Coffee, CYP1A2 Genotype, and Risk of Myocardial Infarction." JAMA 2006;295(10):1135–1141 — the CYP1A2*1F and *1A alleles; 2,014 cases and 2,014 controls in Costa Rica, 1994 to 2004; the 54 per cent carrier frequency; every odds ratio in the table; the age-stratified results; and the 250 ml cup.
Orrje E, Fristedt R, Rosqvist F, Landberg R, Iggman D. "Cafestol and kahweol concentrations in workplace machine coffee compared with conventional brewing methods." Nutrition, Metabolism and Cardiovascular Diseases 2025;35(8):103933 — every cafestol and kahweol concentration cited, including the fabric-filter figures, and the estimated 0.58 mmol/L reduction in LDL cholesterol.
EFSA Panel on Dietetic Products, Nutrition and Allergies. "Scientific Opinion on the safety of caffeine." EFSA Journal 2015;13(5):4102 — 400 mg daily and 200 mg single dose for adults; 200 mg daily in pregnancy and lactation; the 3 mg/kg equivalence; the blood pressure conclusion; and the insufficiency of data for children and adolescents.
American Heart Association. "Coffee and heart health: How many cups of caffeinated coffee are safe to drink each day?" News release, 20 July 2026. https://newsroom.heart.org/news/coffee-and-heart-health-how-many-cups-of-caffeinated-coffee-are-safe-to-drink-each-day — more than four cups and heart failure; the 2026 Dietary Guidance; what scientific statements do.
Lopez-Garcia E, et al. "Coffee consumption and coronary heart disease in men and women: a prospective cohort study." Circulation 2006;113(17):2045–2053. doi:10.1161/CIRCULATIONAHA.105.598664 — no evidence that coffee increases coronary heart disease.
Ding M, et al. "Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts." Circulation 2015;132(24):2305–2315. doi:10.1161/CIRCULATIONAHA.115.017341 — coffee and cardiovascular deaths in three cohorts.
Gunter MJ, et al. "Coffee Drinking and Mortality in 10 European Countries: A Multinational Cohort Study." Annals of Internal Medicine 2017;167(4):236–247. doi:10.7326/M16-2945 — 521,330 participants, 16.4 years, circulatory deaths in women.
Mesas AE, et al. "The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis." American Journal of Clinical Nutrition 2011;94(4):1113–1126. doi:10.3945/ajcn.111.016667 — short-term and two-week blood pressure effects in hypertension.
Teramoto M, et al. "Coffee and Green Tea Consumption and Cardiovascular Disease Mortality Among People With and Without Hypertension." Journal of the American Heart Association 2023;12(2):e026477. doi:10.1161/JAHA.122.026477 — 18,609 adults, 18.9 years, grade 2–3 hypertension.
Joglar JA, et al. "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." Circulation 2024;149(1):e1–e156. doi:10.1161/CIR.0000000000001193 — caffeine abstention.
US Food and Drug Administration. "Spilling the Beans: How Much Caffeine is Too Much?" Content current as of 28 August 2024. https://www.fda.gov/consumers/consumer-updates/spilling-beans-how-much-caffeine-too-much — 400 mg, about two to three 12-ounce cups.
American College of Obstetricians and Gynecologists. Committee Opinion No. 462, "Moderate Caffeine Consumption During Pregnancy." August 2010, reaffirmed 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2010/08/moderate-caffeine-consumption-during-pregnancy — less than 200 mg a day.

Claims this encyclopedia could not source

These statements appear in published material about coffee and the heart. This encyclopedia has not traced them to a primary source and does not assert them.

A population distribution of caffeine metaboliser types, and their half-lives.
The half-life figures of 1.5 to 9.5 hours, and of fifteen hours in late pregnancy, that circulate widely. The AHA and EFSA give the ranges quoted above.
Inferring your own metaboliser status from jitteriness. No validated method for this has been located. Commercial genotype tests exist; no cardiology body recommends them for this purpose.
A figure for the short-term rise in blood pressure from 200 mg of caffeine in people without hypertension. The meta-analysis located measured people with hypertension.
Arterial stiffness in light to moderate coffee drinkers, and whether it translates into reduced stroke risk.
Whether sugar and cream attenuate the associations. Raised in the literature; not settled.
Diterpene content of colador-brewed Puerto Rican coffee, or of stovetop moka pot coffee. No published measurement located.
CYP1A2*1F allele frequency in Puerto Rico. No study located. Frequencies vary between populations.
Any claim that a particular coffee, roast, origin or brand is better or worse for the heart. No published study supports a cardiovascular claim for any individual coffee brand or origin.
That the Gill umbrella review has been promoted by a coffee-industry-funded body. No source located.

Important Note

This article summarises published research on coffee and cardiovascular outcomes. It is not a substitute for personalised medical advice. Observational studies describe associations across large populations; they do not establish what any individual should do. If you have a heart condition, high blood pressure, an arrhythmia, or are taking medication that interacts with caffeine, discuss coffee consumption with your physician rather than relying on general research summaries.

Medical disclaimer: This article summarizes published peer-reviewed research and is for educational purposes. It does not constitute medical advice. Discuss any cardiovascular concerns and dietary changes with your physician.

Taste Authentic Puerto Rico Coffee

Puerto Rican coffee is grown above 3,000 feet in the central mountains of the island, picked, processed and roasted there.

BUY AUTHENTIC PUERTO RICO COFFEE NOW →

Freshly roasted, shipped worldwide. The real taste of Boricua heritage in every cup.

Part of The Coffee Encyclopedia — the world's largest free coffee reference. Proudly sponsored by PuertoRicoCoffeeShop.com.